Eris Lifesciences Ltd
Eris Lifesciences Ltd (ERIS) last reported results for the quarter ended Jun 2026, with sales of ₹873 crore and net profit of ₹143 crore. The stock last traded at ₹1,185, a market capitalisation of ₹16,440 crore, on a P/E of 25.1. Over the past 52 weeks the stock has ranged between ₹1,163 and ₹1,740. Figures are as of 6 Oct 2026 and are not real time.
Eris Lifesciences Ltd share price and key metrics
- Current price
- ₹1,185
- Market cap
- ₹16,440 cr
- Stock P/E
- 25.1
- Book value
- ₹282
- ROE
- 18.7%
- ROCE
- 14.1%
- Dividend yield
- 0.61%
- 52w high / low
- 1740/1163
Metrics as of 6 Oct 2026. Not real time.
Track Eris Lifesciences Ltd
Cruxal reads every Eris Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Eris Lifesciences Ltd growth and returns
- 10 Years
- 18%
- 5 Years
- 21%
- 3 Years
- 23%
- TTM
- 10%
- 10 Years
- 17%
- 5 Years
- 12%
- 3 Years
- 19%
- TTM
- 69%
- 10 Years
- %
- 5 Years
- 9%
- 3 Years
- 10%
- 1 Year
- -26%
- 10 Years
- 21%
- 5 Years
- 18%
- 3 Years
- 16%
- Last Year
- 19%
Eris Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹873 cr, up 12.9% from ₹773 cr a year earlier. Net profit was ₹143 cr, up 14.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| Expenses | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 |
| Operating profit | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 |
| OPM % | 36% | 34% | 36% | 36% | 36% | 35% | 36% | 34% |
| Other income | 5 | 4 | 8 | 4 | 3 | -17 | 2 | 2 |
| Interest | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 |
| Depreciation | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 |
| Profit before tax | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 |
| Tax % | 25% | 25% | 21% | 22% | 22% | 25% | -75% | 20% |
| Net profit | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 |
| EPS (₹) | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 | 10.28 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Eris Lifesciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 | 3,230 |
| Operating profit | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,120 | 1,138 |
| OPM % | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% | 36% | 35% |
| Net profit | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 | 666 |
| EPS (₹) | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 44.72 | 46.75 |
TTM is the trailing twelve months to the most recent quarter.
Eris Lifesciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 | 3,889 |
| Borrowings | 1 | 377 | 176 | 0 | 7 | 84 | 877 | 2,781 | 2,478 | 2,359 |
| Other liabilities | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,366 | 1,415 | 861 |
| Total liabilities | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,747 | 7,123 |
| Fixed assets | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,188 |
| CWIP | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 171 |
| Investments | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 62 |
| Other assets | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,307 | 1,702 |
| Total assets | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,747 | 7,123 |
As reported by the company. Total assets equal total liabilities by construction.
Eris Lifesciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 | 538 |
| Cash from investing | -184 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -78 | -369 |
| Cash from financing | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 | -314 |
| Net cash flow | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 105 | -145 |
| Free cash flow | 150 | 210 | 186 | 125 | 350 | 258 | -550 | 357 | 910 | 241 |
| CFO / operating profit | 94% | 94% | 85% | 87% | 103% | 94% | 68% | 87% | 114% | 59% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Eris Lifesciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 60% | 34% | 26% | 25% | 27% | 25% | 17% | 11% | 12% | 14% |
| Debtor days | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 | 79 |
| Inventory days | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 | 200 |
| Days payable | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 210 | 170 | 151 |
| Cash conversion cycle | 84 | -40 | 28 | -12 | 30 | 44 | 70 | 48 | 59 | 129 |
| Working capital days | 23 | -13 | -17 | 59 | 64 | 75 | 50 | -296 | -49 | -71 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Eris Lifesciences Ltd shareholding pattern
Promoters held 54.14% at Jun 2026, down from 54.83% at Jun 2025. FIIs 5.76% and DIIs 20.71%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.87% | 54.86% | 54.85% | 54.83% | 54.85% | 54.85% | 53.92% | 54.14% |
| FIIs | 8.01% | 8.36% | 8.43% | 8.39% | 7.21% | 6.85% | 6.39% | 5.76% |
| DIIs | 18.64% | 18.07% | 18.07% | 18.18% | 19.36% | 20.31% | 20.35% | 20.71% |
| Public | 18.47% | 18.73% | 18.64% | 18.59% | 18.57% | 17.97% | 19.33% | 19.39% |
| No. of shareholders | 46,346 | 53,314 | 50,087 | 52,225 | 59,438 | 54,713 | 51,656 | 50,798 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Eris Lifesciences Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: As Attached
Read the full analysis - Eris Lifesciences Limited resigns COO Krishnakumar Vaidyanathan effective September 30, 2026, with no immediate financial impact disclosedCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences Limited has announced the resignation of its Chief Operating Officer…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: As Attached
Read the full analysis - Eris Lifesciences Limited concludes 20th Annual General Meeting with successful passage of all resolutionsAGM/EGMlow impact
Cruxal's analysis: Eris Lifesciences Limited has successfully concluded its 20th Annual General Meeting held…
Read the full analysis - Eris Lifesciences Limited concludes 20th Annual General Meeting with routine business resolutionsAGM/EGMlow impact
Cruxal's analysis: Eris Lifesciences Limited has successfully concluded its 20th Annual General Meeting held…
Read the full analysis - Eris Lifesciences Ltd announces allotment of equity sharesCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences Ltd has filed an announcement regarding the allotment of equity shares…
Read the full analysis - Eris Lifesciences appoints Akhil Awasthi as Independent Director to strengthen board governanceCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences Limited has announced the appointment of Mr. Akhil Awasthi as an…
Read the full analysis - Eris Lifesciences Limited Announces Resignation of Executive Director and COO Krishnakumar VaidyanathanCompany Updatemedium impact
Cruxal's analysis: Eris Lifesciences Limited has formally announced that Mr. Krishnakumar Vaidyanathan, the…
Read the full analysis - Eris Lifesciences Ltd issues clarification on market rumors under Regulation 30(11)Company Updatelow impact
Cruxal's analysis: Eris Lifesciences has filed a disclosure under Regulation 30(11) of the SEBI (LODR)…
Read the full analysis - Eris Lifesciences Ltd announces availing of term loan facility from Axis BankCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has disclosed the availing of a term loan facility from Axis Bank under…
Read the full analysis - Eris Lifesciences Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has issued an intimation regarding an upcoming analyst/investor…
Read the full analysis - Eris Lifesciences Ltd: Disclosure of Newspaper Publication regarding Regulation 30Company Updatelow impact
Cruxal's analysis: Eris Lifesciences has published a notice in newspapers in compliance with Regulation 30…
Read the full analysis - Eris Lifesciences Ltd: Disclosure of Newspaper Publication regarding Regulation 30Company Updatelow impact
Cruxal's analysis: Eris Lifesciences has fulfilled its statutory obligation under Regulation 30 of the SEBI…
Read the full analysis - Eris Lifesciences Ltd files Business Responsibility and Sustainability Report (BRSR)Otherslow impact
Cruxal's analysis: Eris Lifesciences has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Eris Lifesciences Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Eris Lifesciences has submitted its Annual Report for the financial year 2025-26 in…
Read the full analysis - Eris Lifesciences Limited Announces 20th Annual General Meeting for September 25, 2026AGM/EGMlow impact
Cruxal's analysis: Eris Lifesciences Limited has issued a notice for its 20th Annual General Meeting (AGM)…
Read the full analysis - Eris Lifesciences Limited announces re-appointment of Independent Director and schedules 20th Annual General MeetingOtherslow impact
Cruxal's analysis: Eris Lifesciences Limited has formally announced the re-appointment of Mr. Sujesh…
Read the full analysis - Eris Lifesciences schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has issued an intimation regarding an upcoming analyst/investor…
Read the full analysis - Eris Lifesciences Ltd schedules analyst and investor meetingCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has issued an intimation regarding an upcoming analyst and investor…
Read the full analysis - Eris Lifesciences schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has issued an intimation regarding an upcoming analyst/investor…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.